Dr Md Ezharul Hoque Chowdhury

Associate Professor

Jeffrey Cheah School of Medicine & Health Sciences

Email: md.ezharul.hoque@monash.edu
Tel: +603 5515 9660
Office: Room 4-4-25

Profile Summary

Associate Professor Ezharul joined the Monash University Malaysia campus in February 2011 as a senior lecturer. Prior to this appointment, he was a senior lecturer at International Medical University (IMU) since September 2008 and a tenure-track assistant professor of Tokyo Institute of Technology since 2006. He has pioneered the development of carbonate apatite as a smart tool for efficient and targeted intracellular delivery of genetic materials, gene-silencing elements, proteins and classical anti-cancer drugs. He has created a new branch of nanomedicine delivery based on this pH-sensitive inorganic nano-carrier. His research team is one of the leading groups in the world working in the relevant area. His outstanding contributions have so far produced over 50 publications in the highly cited journals and 5 Japanese and US patents, some of which have already being commercialized. His research profile can be found in the following websites:

http://umonash-my.academia.edu/EzharulHoqueChowdhury
https://www.researchgate.net/profile/Ezharul_Chowdhury/publications

Qualifications

2012-2014: Graduate Certificate in Higher Education, Monash University, Australia

2000-2003: Doctor of Engineering in Biomolecular Engineering, Tokyo Institute of Technology, Tokyo

1998-2000: Master of Science in Biochemistry, University of Dhaka, Dhaka, Bangladesh

1993-1998: Bachelor of Science in Biochemistry, University of Dhaka, Dhaka, Bangladesh

Employment History

2011- 2013: Senior Lecturer, Monash University (Sunway Campus)

2008- 2011: Senior Lecturer, International Medical University

2006- 2008: Assistant Professor (Independent), Tokyo Institute of Technology

2006- 2008: Visiting Professor & Lab Chief, Shizuoka Cancer Center Research Institute

2006- 2006: Researcher & Group Leader, Tokyo Institute of Technology

2006- 2006: Visiting Researcher & Lab Chief, Shizuoka Cancer Center Research Institute

2004- 2006: Research Fellow of JSPS, Tokyo Institute of Technology

2003- 2004: Post-doctoral Researcher, Tokyo Institute of Technology

Teaching Experiences

Dr Md. Ezharul Hoque Chowdhury has been teaching for the last 8 years since 2004

Taught courses in Tokyo Institute of Technology, 2004 – 2008 :

  • Biomedical Engineering
  • Nanobiotechnology
  • Tissue Engineering
  • Drug delivery
  • Biomaterials
  • Molecular diagnosis
  • Cell signaling
  • Cancer=

Taught courses in International Medical University (IMU) and Monash University Malaysia, 2008 - Present:

  • Pharmaceutics
  • Cell and molecular biology
  • Toxicology and toxinology
  • Pharmacology
  • Biochemistry
  • Microbiology
  • Nanobiotechnology
  • #total of 5 items#
  • Practice-based learning (PBL) for the following modules:
  • Respiratory system
  • Cardiovascular system
  • Gastrointestinal system
  • Haematology
  • DNA finger printing

Administrative Activities

  • Coordination of ‘Master of Biomedical Science’ program
  • Involvement in accreditation of current and new programs
  • Coordination of courses at Tokyo Tech and International Medical University

Editing and reviewing journal papers

Dr Md. Ezharul Hoque Chowdhury is one of the editorial board members for International Journal of Nanomedicine, Drugs and Therapy Studies, OA cancer, Journal of Cancer Metastasis and Treatment and Journal Recent Patents on Drug Delivery & Formulation.

He is also the editor of submitted research papers for the conference proceedings in Tsinghua - Tokyo Tech & Shizuoka Cancer Center Triangle Symposium on Cancer Biology & Bioengineering” 2006, Oct 27, 2006, Shizuoka, Japan and The 1st International Symposium on Cancer Therapy and Regenerative Medicine, Oct 6, 2007, Shizuoka, Japan.

Research & Education

Leading a research team for a consecutive period of 13 years

Dr Md. Ezharul Hoque Chowdhury has been leading a research team since 2004. In Tokyo Tech, he was responsible for all of the research activities of a research group consisting of 5 undergraduate and postgraduate (Japanese and international) students. When he moved to Shizuoka Cancer Research Institute as a visiting professor, he had to establish a new lab in the Institute for a small group (3 members). Simultaneously he had to frequently visit Tokyo Tech (Yokohama campus) for supervising the students in the former group. He successfully got a big research grant from Japan Science and Technology (JST) corporation and he has, thus, the experience of budgeting for the entire research scheme and hiring a post-doct. In IMU, he has already formed his own research group with undergraduate and post-graduate students and recruited a research assistant. Since here he is also the principal investigator of a MOSTI-approved research grant, he has to manage the whole project by communicating with MOSTI and IMU postgraduate research division.

Publications

Single-authored Book

Chowdhury, E. H. Nanotherapeutics: From Laboratory to Clinic. CRC Press, 2016 (In press).  The most comprehensive, harmonious, illustrative, and up-to-date book on nanotherapeutics or nanomedicine. Link: https://www.crcpress.com/Nanotherapeutics-From-Laboratory-to-Clinic/Chowdhury/9781498707510

Original research papers (selected)

Tiash S, Kamaruzman NIB, Chowdhury EH. Carbonate apatite nanoparticles carry siRNA(s) targeting growth factor receptor genes egfr1 and erbb2 to regress mouse breast tumor. Drug Deliv. 2018 Nov;24(1):1721-1730 (Impact factor 6.4).

Mehbuba Hossain S, Chowdhury EH. Citrate- and Succinate-Modified Carbonate Apatite Nanoparticles with Loaded Doxorubicin Exhibit Potent Anticancer Activity against Breast Cancer Cells. Pharmaceutics. 2018 Mar 11;10(1). (Impact factor 3.83)

Fatemian T, Chowdhury EH. Cytotoxicity Enhancement in Breast Cancer Cells with Carbonate Apatite-Facilitated Intracellular Delivery of Anti-Cancer Drugs. Toxics. 2018 Feb 5;6(1).

Sheikh Tanzina Haque and Ezharul Hoque Chowdhury. Recent Progress in Delivery of Therapeutic and Imaging Agents Utilizing Organic-Inorganic Hybrid Nanoparticles. Current Drug Delivery, 2017. (Impact factor 2.25)

Fitya Syarifa Mozar and Ezharul Hoque Chowdhury. Impact of PEGylated Nanoparticles on Tumor Targeted Drug Delivery. Current Pharmaceutical Design,2018. (Impact factor 3.45)

Fitya Syarifa Mozar and EzharulHoque Chowdhury. PEGylation of carbonate apatite nanoparticles prevents opsonin binding and enhances tumor accumulation of gemcitabine. Journal of Pharmaceutical Sciences, 2018 (Impact factor 2.7)

Md. Emranul Karim, Kyi Kyi Tha, Iekhsan Othman, Mohammad Borhan Uddin & Ezharul Hoque Chowdhury. Therapeutic potency of nanoformulations of siRNAs and shRNAs in animal models of cancers. Pharmaceutics. 2018 (Impact factor 3.83)

Mozar FS, Chowdhury EH. Surface-Modification of Carbonate Apatite Nanoparticles Enhances Delivery and Cytotoxicity of Gemcitabine and Anastrozole in Breast Cancer Cells. Pharmaceutics. 2017 Jun 7;9(2) (Impact factor 3.83).

Tiash S,, ChowdhuryEH. Knockdown of ROS1 gene sensitizes breast tumor growth to doxorubicin in a syngeneic mouse model. Int J Oncol. 2016 (In Press) (Impact factor 3.03).

Tiash S, Chowdhury EH. Passive targeting of cyclophosphamide-loaded carbonate apatite nanoparticles to liver impedes breast tumor growth in a syngeneic model. Curr Pharm Design. 2016 (In press) (Impact factor 3.45).

Mozar FS, Chowdhury EH. Gemcitabine interacts with carbonate apatite with concomitant reduction in particle diameter and enhancement of cytotoxicity in breast cancer cells. Curr Drug Deliv. 2015;12(3):333-41 (Impact factor 2.25).

Ahmad A, Othman I, Md Zain AZ, Chowdhury EH. Controlled release of insulin in blood from strontium-substituted carbonate apatite complexes. Curr Drug Deliv. 2015;12(2):210-22 (Impact factor 2.25).

Kunnath, A.P., Tiash, S., Fatemian, T., Morshed, M., Shar, S.M.,  Chowdhury, E. H. Intracellular delivery of ERBB2 siRNA and p53 gene synergistically inhibits the growth of established tumor in an immunocompetent mouse. J Cancer Sci Ther , 2014: 6: 099-104. (Impact factor 5.8).

Yusuf, S., Chowdhury, E. H., Rosli, R., Hassan, F and Abdullah, S. Gene delivery potential of bio functional carbonate apatite nanoparticles in lungs. BioMed Research International, 2014;2014:646787. (Impact factor 2.88).

Tiash, S., Othman, I., Rosli. R., Chowdhury, E.H. Methotrexate- and cyclophosphamide-embedded pure and strontiumsubstituted carbonate apatite nanoparticles for augmentation of chemotherapeutic activities in breast cancer cells. Curr Drug Deliv. 2014, 2014;11(2):214-22 (Impact factor 2.25).

Kunnath AP, Kamaruzman NI, Chowdhury EH. Nanoparticle-facilitated Intratumoral Delivery of Bcl-2/IGF-1R siRNAs and p53 Gene Synergistically Inhibits Tumor Growth in Immunocompetent Mice. Journal of Nanomedicine and Nanotechnology, 2014, 6(2), 1-9  (Impact factor 5.72).

Hossain, S., Yamamoto, H., Chowdhury, E. H., et al. Fabrication and intracellular delivery of doxorubicin/carbonate apatite nanocomposites: Effect on growth retardation of established colon tumor. PLoS One. 2013, 16; 8(4):e60428. (Impact factor 4.092).

Hossain S, Sultana N, Chowdhury EH. PKC Activation Promotes Internalization of DNA-Immobilized Inorganic Nano-Crystals by Clathrin-Dependent Endocytosis for Efficient Transgene Expression in Human Lymphocytes.  J Nanomed Nanotechol, 2013, 4:174. (Impact factor 5.72).

Chua MJ, Snigdha Tiash, Fatemian T, Noordin MI, Keng CS & Chowdhury EH. Carbonate apatite-facilitated intracellular delivery of c-ROS1 siRNA sensitizes MCF-7 breast cancer cells to cisplatin and paclitaxel. OA Cancer, 2013 Jun 19;1(1):7. (Impact factor has yest to released).

Review Papers (selected)

Ashaie, M. A. & Chowdhury, E. H. Cadherins: the superfamily critically involved in breast cancer.  Current Pharmaceutical Design, 2015 (In press) (Impact factor 3.45).

Bakhtiar, A., Sayyad, M., Rosli, R., Maruyama, A. & Chowdhury, E. H. Intracellular delivery of potential therapeutic genes: Prospects in cancer gene therapy. Current Gene Therapy. 2014;14(4):247-57. (Impact factor 5.3).

Fatemian T, Chowdhury EH. Targeting oncogenes and tumor suppressors genes to mitigate chemoresistance. Curr Cancer Drug Targets. 2014;14(7):599-609 (Impact factor 3.58).

Fatemian, T, Othman, I & Chowdhury, E. H. Strategies and validation for siRNA-based therapeutics for reversal of multi-drug resistance in cancer, Drug Discovery Today, 2014 19(1):71-8 (Impact factor 6.5).

Book Chapters

Chowdhury, E. H. pH-sensitive nanocrystals of carbonate apatite- a powerful and versatile tool for efficient delivery of genetic materials to mammalian cells, “Advances in Biomaterials Science and Applications in Biomedicine”. Eds., Pignatello R, InTech, Croatia, 2013.

Hossain, S, Chowdhury, E. H. and Akaike, T. Inorganic nanomaterials of carbonate apatite as intracellular nucleic acid/drug transporters,” Bioengineered Nanomaterials’, Eds., Atul Tiwari; Ashutosh Tiwari, Linköping University, Sweden, 2013, 149–162.

International Patents

E. H. Chowdhury. Patent title: Bio-responsive nano-materials for efficient therapeutic transport. Malaysian Patent Application No. PI2014702983. Filing Date: 10/10/2014.

E. H. Chowdhury and T. Akaike. Patent title: Purification of plasmid DNA. Japanese Patent Application No. 2005-192605. Filing Date: 30/06/2005.

E. H. Chowdhury and T. Akaike. Patent title: Plasmid DNA delivery through integrin. Japanese Patent Application No. 2005-232504. Filing Date: 10/08/2005.

E. H. Chowdhury and T. Akaike. Patent title: Mg2+-inspired nano-apatite generation for high efficiency gene delivery into mammalian cells. Provisional US Patent Application No. 60/532,845. Filing Date: 12/26/2003. PCT Application No. PCT/JP2004/019549. Filing Date: 27/12/2004.

E. H. Chowdhury, F.T. Zohra and T. Akaike. Patent title: mRNA delivery with apatites. Japanese Patent Application No. 2005-252057. Filing Date: 31/08/2005.

E. H. Chowdhury, A. Maruyama and T. Akaike. Patent title: Gene-delivery Method. Provisional US Patent Application No. 60/425,291. Filing Date: 11/12/2002. PCT Application No. PCT/JP03/14376. Filing Date: 12/11/2003. PCT Publication Date: 27/05/2004; Patent No. WO 2004/043495. Japanese Patent Publication Date: 23/03/2006; Patent No. 2006-509838.

Research Grants

Competitive Research Grants as Principal Investigator (PI)

2004-2006: Super-efficient DNA/RNA Delivery for Cell-specific Therapy Based on Carbonate Apatite Nano-particles (Japan Society for the Promotion of Science) (JPY: 1,500,000).

2006-2008: Cancer therapy through cell-specific delivery of genes and gene-silencing components by using multifunctional, pH-sensitive inorganic nano-particles (Japan Science and Technology Corporation) (JPY: 22,000,000).

2008-2009: Gene Delivery to Leukemia Cells using Bio-Functional Carbonate Apatite Nano-Particles (IMU 172/08) (RM 20,000).

2009-2010: Gene silencing for inhibition of cancer cell proliferation and survival: A new strategy for cancer therapy (BMS I01-2009(06)) (RM 20,000).

2009-2009: Delivery of anti-cancer drugs to breast cancer cells using nano-particles (Bpharm B0106_Res1912009) (RM 5,000).

2009-2009: Efficient isolation of high quality Plasmid DNA from bacteria (Bpharm B0106_Res182009) (RM 10,000).

2010-2010: Nanoparticle-mediated Delivery of Small Interfering RNAs (siRNAs) Against "Cell Adhesion receptor" Genes for Tumor Cell Killing in Presence of Absence of Anti-Cancer Drugs (BPharm B0107_Res(16)2010) (RM 10,000).

2010-2010: Silencing of ABC Transporter Genes with Nanoparticle-mediated Delivery of Small Interfering RNAs (siRNAs) for induction of Apoptosis in cancer Cells (BPharm B0107_Res(17)2010) (RM 5,000).

2011-2011: Intracellular Proteinase delivery using pH-sensitive Nanoparticles for anti-Tumor Activity. (MB I 01/2008(01)2010) (RM 10,000).

2011-2011: Silencing of Tyrosine Kinase Gene Expression for Inhibition of Cancer Cell Proliferation and Survival (MB I01/2008(02)2010) (RM 10,000).

2009-2011: Targeted delivery of anti-cancer drugs to breast cancer cells using bio-functional carbonate apatite nano-particles (E-Science Project ID 02-02-09-SF0013) (RM 205,000).

2011-2011: Oral delivery of insulin embedded with carbonate apatite nano-particles: Protection against enzymatic degradation, transcellular and controlled release in blood. (Project code: M-CAR-RS (RM 20,000).

2010-2012: Inhibition of cancer cell proliferation and survival through synergistic effects of traditional anti Cancer drug action in combination with targeted knockdown of cancer-related genes (IMU 219/2010) (RM 40,000).

2012-2012: Super-sensitive biosensor development based on monoclonal antibody-immobilized nanoparticles for early detection of dengue virus (Budget code: 5140028 (RM 30,000).

2013-2013: Investigating the effects of physico-chemical and biological parameters affecting quality of Halal Meat (RM 20,000).

2010-2013: Induction of Apoptosis in Breast Cancer Cells through Combined Intracellular Delivery of a Tumor suppressor Gene and Small interfering RNAs Against Growth Factor Receptor and anti-apoptotic Genes (IMU 220/2010) (RM 60,000).

2013-2014: Development of bio-responsive inorganic nano-crystals and implementation in conventional drug delivery, gene therapy and tissue engineering. Seed grant from Advanced Engineering Platform (AEP), Monash University (Sunway Campus) (RM 54,000)

2012-2014: Targeted delivery of small interfering RNAs (siRNAs) against oncogenes using pH-sensitive nanoparticles for inhibition of cancer cell proliferation and survival (E-Science Project ID Project ID: 02-02-10-SF0083) (RM 296,000).

2013-2014: Breast cancer-targeted delivery of anti-cancer drugs using pH-sensitive inorganic nanoparticles, JCSMH grant for supporting MBioMedSc research project (RM 10,000).

2014-2014: Anti-cancer drug transport to breast cancer cells using mineral nanoparticles, JCSMH grant for supporting BMedSc research project (RM 10,000).

2014-2014: Intracellular delivery of small interfering RNAs (siRNAs) for inhibition of proliferation/survival and augmentation of chemotherapeutic effects in breast cancer cells, JCSMH grant for supporting BMedSc research project (RM 10,000).

2014-2015: Investigation of Breast Cancer Growth and Metastasis Inhibition in Response to Overexpression of P53 Gene and Targeted Knockdown of Growth Factor Receptor and Anti-Apoptotic Genes (FRGS, MOHE) (RM 125,000).

2015-2017: Multi-functionalcancer nano-therapeuticsdeliveringa cocktail of classical drugs, tumor suppressor genes and anti-sense RNAsto blockmulti-drug resistance and cancer progression (E-Science Project ID Project ID: 02-02-10-SF0299) (RM 198,000).

Research Supervision

Supervisions at Monash University Malaysia

Doctoral students

Ms. Snigdha Tiash, Title: Apoptosis induction in cancer cells with nanoparticle-facilitated delivery of classical anti-cancer drugs and siRNAs targeting growth factor receptor and multi-drug transporter genes (completed, currently working as a post-doct at University of Melbourne, Australia)

Ms. Tahereh Fatemian, Title: Intracellular delivery of p53, oncogenic siRNAs and anti-cancer drugs using pH-sensitive inorganic nanoparticles for induction of apoptosis in breast cancer cells

Ms. Nur Izyani Kamaruzman, Title: Targeted delivery of small interfering RNAs (siRNAs) against oncogenes using pH-sensitive nanoparticles for inhibition of cancer cell proliferation and survival

Ms. Athirah Bakhtair, Title: Development of novel inorganic nano-crystals for delivery of plasmid DNA and siRNA to mammalian cells

Mr. Anil Philips Kunath, Title: Induction of Apoptosis in Breast Cancer Cells through Combined Intracellular Delivery of a Tumor suppressor Gene and Small interfering RNAs Against Growth Factor Receptor and anti-apoptotic Genes

Mr Syafiq Asnawi Zainal Abidin. Disintegrins and cytotoxins from Malaysian Vipers and their mechanisms of action on human colorectal cancer cells

Ms. Nabilah Baby. Breast cancer-targeted delivery of tumor suppressor genes,     oncogene-specific siRNAs and classical anti-cancer drugs using monoclonal antibody-coated inorganic nanoparticles

Ms. Jayalaxmi Shetty. Development of bio-functional inorganic nanoparticles for efficient delivery of siRNA, therapeutic gene and anti-cancer drugs to breast cancer cells

Rahela Zaman. Fabrication of Oral Nano-Insulin Formulation for Regulating Blood Glucose Level

Ahsanul Kaiser. Laser-responsive drug delivery and imaging to targeted cancer cells based on carbonate apatite nanoparticles

Maeirah Ashaie, Perturbation of cell-cell and cell-macromolecule interactions and their associated signalling cascades by biodegradable nanoparticle-assisted delivery of siRNA and study of consequential chemosensitization of breast cancer

Master-by-research student

Mr. Suleiman Haji, Title: Intranasal delivery of plasmid DNA using carbonate apatite nanoparticles (completed).

Chua Ming Jang. Inhibition of cancer cell proliferation and survival through synergistic effects of traditional anti-cancer drug action in combination with targeted knockdown of cancer-related genes

Ms. Fitya Syarifa, Title: Breast cancer-targeted delivery of anti-cancer drugs using pH-sensitive inorganic nanoparticles.

BMedSc student:

Mr. Aiman Ahmad, Title: Controlled release of insulin from insulin-apatite nano-composites for the treatment of diabetes (completed, currently working in Qatar as a medical doctor)

Mr. Mohammad Fahad Sorefan, Title: Intracellular delivery of small interfering RNAs (SiRNAs) for inhibition of proliferation/survival and augmentation of chemotherapeutic effects in breast cancer cells (completed, currently working in Australia as a medical doctor)

Ms. Chong Chia Yuen, Title: Anti-Cancer drug transport to breast cancer cells using mineral nanoparticles (completed, currently working in Australia as a medical doctor)

Supervisions at Tokyo Tech

Doctoral students:

K. Kutsuzawa ‘Extracellular matrix (ECM) protein-coated carbonate apatite particles for gene delivery to mouse embryonic stem cells’ (completed, currently working as a post-doct, Tokyo Institute of Technology, Japan)

‘Apatite-liposome hybrid carrier for efficient mRNA delivery’ (completed, currently working as a post-doctoral, Drexel University College of Medicine, USA)

‘Design of carbonate apatite nano-carrier for siRNA and anti-cancer drug delivery’ (completed, currently working as an Assistant Professor, Jahangirnagar University, Dhaka, Bangladesh)

Master student
Dr Md. Ezharul Hoque Chowdhury has supervised one master student as a co- supervisor at Tokyo tech with the title ‘Development of an anti-cancer drug delivery system based on carbonate apatite nanoparticles’ (completed)

Undergraduate student:
Dr Md. Ezharul Hoque Chowdhury has also supervised an undergraduate student as the main supervisor on the topic of ‘leukemic cell transfection by carbonate apatite nanoparticles’ (completed)

Student Supervisions at International Medical University (IMU)

Master students
Ms. Ming Jang Chua, Title: Inhibition of Cancer Cell Proliferation and Survival Through Synergistic Effects of Traditional Anti Cancer Drug Action in Combination with Targeted Knockdown of Cancer-related Genes (completed, currently working as a doctoral student, Griffith University, Brisbane, Australia)

Undergraduate students (completed)
1 BMed Science student
7 Pharmacy students
4 Medical Biotechnology students at IMU

Academic Awards

  • 2000-2003: Monbusho (Ministry of Education, Science, Sports and Culture) Scholarship, the most honorable scholarship in Japan
  • 2004-2006: JSPS Fellowship, the most prestigious post-doctoral fellowship in Japan
  • Outstanding oral presentation award at ICBME held in Singapore (2005)
  • Tejima Memorial Prize of Japan (2007)
  • Monash Pro-Vice Chancellor (PVC) Award for Excellence in Research (2011)
  • Monash Pro-Vice Chancellor (PVC) Award for Excellence in Research (2012)
  • Monash Pro-Vice Chancellor (PVC) Award for Excellence in Research (2013)
  • Gold Medal in 27th International Invention & Innovation Exhibition (ITEX) (2016)

Invited Talks

  • The impact of nanotherapeutics in transforming the medicine.  International Conference on Medical Science Technology (ICMST). 23-24 November 2016, Grand ballroom Hotel Bangi Putrajaya (Plenary speech)
  • pH-sensitive inorganic nano-crystals for smart and targeted delivery of anti-cancer drugs and small interfering RNA (siRNA). International Research Symposium on Engineering and Technology (IRSET). 13-15 September, 2016, M Hotel Singapore (Keynote speech).
  • pH-sensitive inorganic nanoparticles for efficient delivery of anticancer drugs to breast cancer cells. 2nd International Conference on Innovations in Engineering and Technology (ICCET’2014). Sep 19-20, 2014, Bayview Hotel Georgetown, Penang.
  • Nanomedicine delivery with bio-functional inorganic nano-particles. International Meeting on New Trends in Biotechnology. Monash University Malaysia, Dec 12-13, 2013.
  • Targeted gene knockdown for reversal of multi-drug resistance in cancer. Bio-IT World Asia Conference. Marina Bay Sands, Singapore, May 28-31, 2013.